The Ministry of Health, Biological Laboratories and Reagents of Mexico (BIRMEX), and Pfizer have signed a Memorandum of Understanding (MOU) aimed at strengthening collaboration between the public sector and the pharmaceutical industry to expand national capabilities in research, production, and access to health technologies.
The agreement seeks to promote technology transfer, especially in the field of messenger RNA (mRNA) platforms, as well as to promote the development of scientific infrastructure and specialized talent in the country. This initiative is part of the objectives of the Plan Mexico, a strategy that seeks to strengthen innovation, sanitary self-sufficiency, and preparedness for public health emergencies.
The Memorandum was signed by the Secretary of Health, David Kershenobich; the General Director of BIRMEX, Carlos Alberto Ulloa Pérez; and the President and General Director of Pfizer Mexico, Juan Luis Morell Villarias. The signing of this instrument establishes a framework of cooperation aimed at strengthening the country's capabilities in accessing, developing, and producing biomedical technologies, particularly those linked to mRNA biotechnology.
Secretary Kershenobich highlighted that Plan Mexico includes developing national capabilities for vaccine production as one of its priority axes. The official emphasized that strengthening these capabilities will increase the country's sanitary sovereignty and improve preparedness for future health emergencies. In this context, he noted that the pandemic left important lessons for the Mexican health system. According to the Secretary of Health, having its own technological and scientific infrastructure is fundamental to protect the population against global health crises.
One of the central components of the Memorandum is the possibility of promoting technology transfer projects based on messenger RNA, a biotechnological platform used in vaccine development. This process seeks to strengthen Mexico's industrial and logistical capabilities in the field of vaccine production, as well as to expand the possibilities of scientific research. In the words of the Secretary of Health, "Mexico must strengthen its capabilities to produce and manage vaccines," as recent experience has shown that having its own technology is key to responding to health emergencies.
The agreement also opens opportunities to expand clinical research in the country, as well as to promote scientific training and medical education programs aimed at developing national talent in biomedical areas. This approach seeks to strengthen the Mexican scientific ecosystem, promoting collaboration between public institutions, research centers, and the pharmaceutical industry.
With the signing of this Memorandum of Understanding, the Ministry of Health, BIRMEX, and Pfizer reaffirm their commitment to working jointly to strengthen national capabilities in research, technological development, and vaccine production. The initiative seeks to promote a collaboration model that allows for the expansion of biomedical innovation in Mexico and to strengthen the country's preparedness for future health challenges.
